• WE ARE


our impact

  • $5.0M

    Amount of seed capital invested by Accel-Rx

  • $44.6M

    Amount of money co-invested by external investors

  • 8.9

    Ratio of external funding to Accel-Rx investment

  • $4.96M

    Average dollar amount per deal

  • $45.1M

    Total amount of follow-on

Building a robust pipeline of health innovation companies.



  • Encycle Therapeutics

    Toronto, ON


    Sudbury, ON

  • ImStar Therapeutics

    Vancouver, BC

  • Inversago Pharma

    Montreal, QC

  • KalGene Pharmaceuticals

  • KisoJi Biotechnology

    Toronto, ON

  • SoundBite Medical Solutions

    Montreal, QC

  • SpecificiT

    Montreal, QC

  • Zucara Therapeutics

    Vancouver, BC

Encycle Therapeutics

Investment Date: 2015

Encycle is a biopharmaceutical company with a unique platform technology that enables the rapid synthesis of small drug-like macrocycles, called nacellins. Encycle’s nacellins provide orally bioavailable, non-biologic modulators, with enhanced permeability, allowing for drug absorption through the gut. This technology provides new therapeutic opportunities for previously underserved diseases and ailments, due to previous oral drug delivery complications. Encycle is concurrently screening their nacellin library for new targets of interest.


To find out more, visit encycletherapeutics.com


Investment Date: 2017

Flosonics is a medical device company focused on developing non-invasive sensors to improve the management of critically ill patients. Flosonics Medical’s flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.

ImStar Therapeutics

Investment Date: 2016

ImStar Therapeutics is a biopharmaceutical company, developing a new approach to treat ALS (Amylotrophic Lateral Sclerosis), commonly known as Lou Gehrig’s disease. ALS is a progressive neurodegenerative disease that causes muscle weakness, paralysis, and ultimately respiratory failure. 450,000 people have the condition and every 90 minutes someone is diagnosed with it. Most people with ALS live only 2-5 years after experiencing the first signs of the disease.


ImStar is developing treatments directed at a new proprietary target, TANA (TDP-43 associated NF-kB activation), in a key immune system activation pathway implicated in ALS. This proprietary target could lead to the future development of treatments for ALS as well as other neurodegenerative diseases such as Parkinson’s.


To find out more, visit imstartx.com

Inversago Pharma

Investment Date: 2017

Inversago is developing new generations of peripherally-restricted cannabinoid-1 (CB1) receptor inverse agonists/antagonists for the treatment of Prader-Willi Syndrome, type 1 diabetes, obesity and other metabolic disorders such as non-alcoholoic steatohepatitis (NASH).  Inversago’s technology addresses limitations associated with first generation CB1 blockers, allowing the Company to fully exploit their medical potential.

KalGene Pharmaceuticals

Investment Date: 2017

KalGene Pharmaceuticals is a pre-clinical stage company focused on the development of precision medicine therapeutics to slow the progression of Alzheimer’s disease. Kalgene Pharmaceutical’s lead, KAL-ABP, targeting toxic amyloid beta oligomers, has been shown in animal models of Alzheimer’s Disease to cross the blood-brain barrier and to significantly reduce the plaque burden, leading to improved cognition and neuronal connectivity.

KisoJi Biotechnology

Investment Date: 2016

KisoJi is a biotechnology company focused on creating best-in-class drugs based on this novel screening platforms in antibodies, stem cells, and cancer stem cells. Through this platform, KisoJi plans to create next generation antibodies that have unique anti-cancer mechanisms. Such therapeutic antibodies have the potential to treat a wide range of cancers with the potential for limited side effects compared to current treatments due to their differentiating properties.

SoundBite Medical Solutions

Investment Date: 2017

SoundBite Medical Solutions is developing a proprietary shockwave technology to address significant unmet clinical needs in interventional cardiovascular therapy. Through an elegant combination of hardware and software, it can, in a controlled manner, deliver high amplitude shockwave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the arterial vascular system, while leaving healthy, elastic vessel walls largely unharmed.


Investment Date: 2017

SpecificiT Pharma Inc. focuses on developing cellular therapies for hematological cancers that are currently untreatable with chimeric antigen receptor modified T cells (CAR-T) therapies.  The company’s unique approach directs unmodified donor T-cells at Minor Histocompatibility Antigens (“MiHAs”) to safely eliminate cancer cells in patients. In addition, the company is employing a proprietary platform to discover novel tumor neoantigens that would allow this unique immunotherapy approach to be used against solid tumors.

Zucara Therapeutics

Investment Date: 2016

Zucara is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia would dramatically change diabetes disease management, improving both patient health and quality of life.


To find out more, visit zucara.ca

View the next generation of Canada's
health sciences industry


We're here to ensure the health sciences ecosystem in Canada thrives today and flourishes into the future.

As Canada’s health innovation accelerator, we give health science start-ups the support they need to transcend innovations into commercialization. This means we enable companies to grow, mature and become investor-ready.

Our mission

We identify, screen, and support—through capital and expertise—promising early-stage companies developing therapeutics, medical devices, and diagnostics, so they can grow and scale to become the next generation of strong Canadian anchor companies in a globally competitive health sciences sector. We're there at that crucial fork in the road where more money is needed to reach clinical validation, but funding is scarce for early-growth capital.

What People Say

  • "Accel-Rx fills an important gap by effectively focusing on an area where it's extremely challenging for a life-science company to succeed."

    Dr. Jason Field

    President & CEO,
    Life Sciences Ontario

  • "The Accel-Rx team has an impressive depth of knowledge in the health sciences sector. They have built biotech companies themselves. They know the challenges new companies face and this puts them in a solid position to understand, appreciate and enable start-ups to flourish."

    Ali Ardakani


  • “We're pleased to join the Accel-Rx portfolio of innovative companies and are grateful for their role in securing the two lead investors and spearheading the diligence efforts. Involvement of Accel-Rx was instrumental in the success of this round and will enable Inversago to advance its program into clinical trials.”

    Francois Ravenelle

    CEO & Founder,

  • "Thanks to Accel-Rx, we've received unfiltered, honest and constructive advice from CEO round-table discussions to high-quality and insightful investor feedback on pitching and fundraising. We appreciate the networking opportunities to meet companies, entrepreneurs and investors. We've had follow up with strategic investors and value-add collaborations with other early-stage medical device companies."

    Joe Eibl


  • “Accel-Rx goes the extra mile in organizing quality events which enable entrepreneurs like myself to connect with international leaders in the venture capital and pharmaceutical industry. Accel-Rx provides unique environments for having meaningful and personal interactions with key stakeholders who can catalyze the development of our companies.”

    Pierre Beauparlant

    President & CEO,
    SpecificiT Pharma

  • There has been great wealth generation in the life science sector in Canada over the years and organizations like Accel-Rx, along with a healthy venture capital community, are playing a significant role in ensuring that the sector continues to be an important value creator for Canadians.

    Daniel Hetu

    Managing Director,
    Lumira Capital

  • As a health sciences focused accelerator, Accel-Rx plays a key role in bringing technologies, entrepreneurs & investors together to enable more efficient & successful company growth and development.

    Shermaine Tilley

    CTI Life Sciences Fund

  • The establishment of Accel-Rx as the first true life sciences accelerator in Canada provides real value to the angel investor community, particularly as an accelerator with an accompanying seed matching fund opportunity.

    Thealzel Lee

    Founder, E-Fund (Angel Fund) Co-Manager,
    VANTEC Angel Network

  • A central part of Canada's biotech ecosystem, Accel-Rx provides the highly-strategic & impactful foundational investment necessary for the advancement of innovation, company development, and overall growth of Canada’s biotech sector. All told, Accel-Rx is a key player in making Canada a global life sciences leader which will generate significant economic & societal benefits for the country more broadly.

    Andrew Casey

    President & CEO,

view more

learn more about our role in the ecosystem

about us